Strategic partnerships Leverage Rational Vaccines' exclusive license with LSU and its focus on immunomodulatory vaccines to explore co-development, research collaborations, or sponsored programs with academia and biotech firms seeking herpes-related solutions.

Clinical advisory access Engage senior clinical experts and potential advisors connected to Rational Vaccines through their CMO appointment and Clinical Advisory Board leadership to offer outsourced clinical consulting, trial design support, or keynote collaborations.

Early-stage opportunities Target Rational Vaccines at their preclinical stage for strategic funding, grant support, or pilot studies, emphasizing rapid collaboration on novel immunomodulatory approaches and diagnostic tools.

Digital and cloud tech Offer integrated cloud-based research platforms, data management, and secure collaboration tools aligned with their Google Cloud and Microsoft 365 usage to streamline preclinical research workflows.

Funding and commercialization Position through strategic partnerships or milestone-based licensing that complements their current funding (~$29M) to accelerate pipeline progress, enhance manufacturing readiness, and explore regional commercialization.